Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

Open Access 01-01-2016 | Original Article

Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma

Authors: Yoshikazu Harada, Hiroto Izumi, Hirotsugu Noguchi, Akihiro Kuma, Yuichiro Kawatsu, Tomoko Kimura, Shohei Kitada, Hidetaka Uramoto, Ke-Yong Wang, Yasuyuki Sasaguri, Hiroshi Hijioka, Akihiko Miyawaki, Ryoichi Oya, Toshiyuki Nakayama, Kimitoshi Kohno, Sohsuke Yamada

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

The polypeptide N-acetylgalactosaminyltransferase (GalNAc-Ts) family of enzymes regulates the critical initial steps of mucin-type O-glycosylation. Among GalNAc-Ts that may significantly influence cancer biology, thus affecting cell differentiation, adhesion, invasion, and/or metastasis, GalNAc-T3 exhibits a high expression in several human cancers, closely associated with tumor progression and a poor prognosis. However, the expression pattern of GalNAc-T3 in oral squamous cell carcinoma (OSCC) remains obscure. Since postoperative recurrence of even early stage OSCC (ESOSCC) occurs at an early phase, significantly affecting their clinical course and worse outcome, the identification of clinically significant accurate biomarkers is needed. Therefore, we investigated the correlation between the immunohistochemical GalNAc-T3 expression and various clinicopathological characteristics and recurrence using 110 paraffin-embedded tumor samples obtained from patients with surgically resected ESOSCC (T1–2N0). Recurrence was recognized in 37 of 110 (33.6 %) patients. The GalNAc-T3 expression was considered to be strongly positive when 20 % or more of the cancer cells showed positive cytoplasmic staining. Consequently, a strong expression of GalNAc-T3 was observed in 40 patients (36.4 %), showing a close relationship to poor differentiation, the presence of lymphatic and vascular invasion, and recurrence. Univariate and multivariate analyses further demonstrated that the patients with a strong GalNAc-T3+ status had markedly lower disease-free survival (DFS) rates, especially within the first 2 years postoperatively. Therefore, GalNAc-T3 might play a role in the pathogenesis of ESOSCC recurrence, and its immunohistochemical detection potentially predicts a shorter DFS and may be a useful parameter for providing clinical management against ESOSCC in the early postoperative phase.
Appendix
Available only for authorised users
Literature
1.
Sasahira T, Kirita T, Kuniyasu H. Update of molecular pathobiology in oral cancer: a review. Int J Clin Oncol. 2014;19(3):431–6.CrossRefPubMed
2.
Jermal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRef
3.
Tong XJ, Shan ZF, Tang ZG, et al. The impact of clinical prognostic factors on the survival of patients with oral squamous cell carcinoma. J Oral Maxillofac Surg. 2014;72(12):2497–e1–10.CrossRefPubMed
4.
5.
González-García R, Naval-Gías L, Román-Romero L, et al. Local recurrences and second primary tumors from squamous cell carcinoma of the oral cavity: a retrospective analytic study of 500 patients. Head Neck. 2009;31(9):1168–80.CrossRefPubMed
6.
Yanamoto S, Yamada S, Takahashi H, et al. Predictors of locoregional recurrence in T1-2N0 tongue cancer patients. Pathol Oncol Res. 2013;19(4):795–803.CrossRefPubMed
7.
Capote A, Escorial V, Muñoz-Guerra MF, et al. Elective neck dissection in early-stage oral squamous cell carcinoma—does it influence recurrence and survival? Head Neck. 2007;29(1):3–11.CrossRefPubMed
8.
Huang TY, Hsu LP, Wen YH, et al. Predictors of locoregional recurrence in early stage oral cavity cancer with free surgical margins. Oral Oncol. 2010;46(1):49–55.CrossRefPubMed
9.
Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta. 1999;1473(1):67–95.CrossRefPubMed
10.
Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4(1):45–60.CrossRefPubMed
11.
Kitada S, Yamada S, Kuma A, et al. Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer. 2013;109(2):472–81.CrossRefPubMedPubMedCentral
12.
Schwientek T, Bennett EP, Flores C, et al. Functional conservation of subfamilies of putative UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferases in Drosophila, Caenorhabditis elegans and mammals. J Biol Chem. 2002;277(25):22623–38.CrossRefPubMed
13.
Ten Hagen KG, Fritz TA, Tabak LA. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology. 2003;13(1):1R–16R.CrossRefPubMed
14.
Bennett EP, Mandel U, Clausen H. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 2012;22(6):736–56.CrossRefPubMed
15.
Shibao K, Izumi H, Nakayama Y, et al. Expressions of UDP-N-Acetyl-α-D-galactosaminepolypeptide GalNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. Cancer. 2002;94(7):1939–46.CrossRefPubMed
16.
Dosaka-Akita H, Kinoshita I, Yamazaki K, et al. N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers. Br J Cancer. 2002;87(7):751–5.CrossRefPubMedPubMedCentral
17.
Gu C, Oyama T, Osaki T, et al. Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence. Br J Cancer. 2004;90(2):436–42.CrossRefPubMedPubMedCentral
18.
Ishikawa M, Kitayama J, Nariko H, et al. The expression pattern of UDP-N-acetyl-alpha-d-galactosamine:polypeptide N-acetylgalactosaminyl transferase-3 in early gastric carcinoma. J Surg Oncol. 2004;86(1):28–33.CrossRefPubMed
19.
Miyahara N, Shoda J, Kawamoto T, et al. Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder. Clin Cancer Res. 2004;10(6):2090–9.CrossRefPubMed
20.
Yamamoto S, Nakamori S, Tsujie M, et al. Expression of uridine diphosphate N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas. Pathobiology. 2004;71(1):12–8.CrossRefPubMed
21.
Li Z, Yamada S, Inenaga S, et al. Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer. 2011;104(12):1882–9.CrossRefPubMedPubMedCentral
22.
Landers KA, Burger MJ, Tebay MA, et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2005;114(6):950–6.CrossRefPubMed
23.
Inoue T, Eguchi T, Oda Y, et al. Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections—special reference to its association with lymph node metastases. Mod Pathol. 2007;20(2):267–76.CrossRefPubMed
24.
Wang ZQ, Bachvarova M, Morin C, et al. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget. 2014;5(2):544–60.CrossRefPubMedPubMedCentral
25.
Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours, 7th edition. Wiley-Blackwell 2009
26.
Yamamoto E, Kohama G, Sunakawa H, et al. Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer. 1983;51(12):2175–80.CrossRefPubMed
27.
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.CrossRefPubMed
28.
Kimura T, Kitada S, Uramoto H, et al. The combination of strong immunohistochemical mtTFA expression and a high survivin index predicts a shorter disease-specific survival in pancreatic ductal adenocarcinoma. Histol Histopathol. 2015;30(2):193–204.PubMed
29.
Nomoto M, Izumi H, Ise T, et al. Structural basis for the regulation of UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells. Cancer Res. 1999;59(24):6214–22.PubMed
30.
Ishida T, Hijioka H, Kume K, et al. Notch signaling induces EMT in OSCC cell lines in a hypoxic environment. Oncol Lett. 2013;6(5):1201–6.PubMedPubMedCentral
31.
Uramoto H, Izumi H, Ise T, Tada M, et al. p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem. 2002;277(35):31694–702.CrossRefPubMed
32.
33.
Hanley JA. Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging. 1989;29(3):307–35.PubMed
34.
Kawatsu Y, Kitada S, Uramoto H, et al. The combination of strong expression of ZNF143 and high MIB-1 labelling index independently predicts shorter disease-specific survival in lung adenocarcinoma. Br J Cancer. 2014;110(10):2583–92.CrossRefPubMedPubMedCentral
35.
Takeda T, Izumi H, Kitada S, et al. The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma. Tumour Biol. 2014;35(10):10555–69.CrossRefPubMed
36.
Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.CrossRefPubMed
37.
Hagen FK, Van Wuyckhuyse B, Tabak LA. Purification, cloning, and expression of a bovine UDP-GalNAc: polypeptide N-acetyl-galactosaminyltransferase. J Biol Chem. 1993;268(25):18960–5.PubMed
38.
O'Connell BC, Hagen FK, Tabak LA. The influence of flanking sequence on the O-glycosylation of threonine in vitro. J Biol Chem. 1992;267(35):25010–8.PubMed
Metadata
Title
Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma
Authors
Yoshikazu Harada
Hiroto Izumi
Hirotsugu Noguchi
Akihiro Kuma
Yuichiro Kawatsu
Tomoko Kimura
Shohei Kitada
Hidetaka Uramoto
Ke-Yong Wang
Yasuyuki Sasaguri
Hiroshi Hijioka
Akihiko Miyawaki
Ryoichi Oya
Toshiyuki Nakayama
Kimitoshi Kohno
Sohsuke Yamada
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3928-7

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Original Article

Staphylococcal enterotoxin B/texosomes as a candidate for breast cancer immunotherapy

Original Article

Prognostic significance of serum ERBB3 and ERBB4 mRNA in lung adenocarcinoma patients

Original Article

Compound 13, an α1-selective small molecule activator of AMPK, potently inhibits melanoma cell proliferation

Original Article

CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo

Original Article

Contribution of resident and recruited macrophages to the photodynamic intervention of colorectal tumor microenvironment

Original Article

Transforming growth factor-β signaling pathway cross-talking with ERα signaling pathway on regulating the growth of uterine leiomyoma activated by phenolic environmental estrogens in vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits